Xijing Hospital
空军军医大学西京医院
Listed for 26 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Xijing Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌5 papers led1 open trial led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌22 papers led
- Hepatocellular carcinoma肝细胞癌58 papers led
- Stomach cancer胃癌62 papers led7 open trials led
- Hepatoblastoma肝母细胞瘤1 paper led
- Chordoma脊索瘤1 paper led
- Osteosarcoma骨肉瘤18 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤4 papers led
- Neuroblastoma神经母细胞瘤2 papers led
- Ewing sarcoma尤文肉瘤2 papers led
- Multiple myeloma多发性骨髓瘤2 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
- IgG4-related diseaseIgG4相关性疾病1 paper led
- Moyamoya disease烟雾病2 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎3 papers led
- Takayasu arteritis大动脉炎3 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
- Duchenne muscular dystrophy杜氏肌营养不良0 papers led
- Behçet disease白塞病1 paper led
- IgA nephropathyIgA 肾病10 papers led
- Gaucher disease戈谢病0 papers led
- Niemann–Pick disease type C尼曼-匹克病 C 型1 paper led
- Primary biliary cholangitis原发性胆汁性胆管炎17 papers led6 open trials led
- Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
- Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
Not listed for: Retinoblastoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.
2 hospitals in Xi'an for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingGNT Induction Treatment in Locally Advanced NPC
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06026878
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingChemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
- Phase
- Phase 3
- Started
- 2022-04
- Registry
- NCT05340491
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen
- RecruitingPD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
- Phase
- Phase 3
- Started
- 2020-03
- Registry
- NCT03907826
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- A novel multimodal adaptive delineation model for primary tumors and lymph node metastases in multi-center nasopharyngeal carcinoma radiotherapy.
- A predictive model based on the dosimetric parameters of the parotid stem cell region to assess the recovery of radiation-induced xerostomia in long-term survivors of nasopharyngeal carcinoma after radical radiotherapy.
- Therapeutic Evaluation of Induction Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma With Low-risk N Stage : A Multicenter Retrospective Study From Nonendemic Region of China.
- Prognostic analysis of 152 patients with distant metastasis after intensity-modulated radiotherapy for nasopharyngeal carcinoma.
- Detailed analysis of recovery process of cranial nerve palsy after IMRT-based comprehensive treatment in nasopharyngeal carcinoma.
All its trials on ClinicalTrials.gov, any status6
- GNT Induction Treatment in Locally Advanced NPC
- GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China
- Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
- PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
- PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
- Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
More papers found outside PubMed (not counted)14
- Development and Validation of a Hybrid Clinical-Delta Radiomics Model to Predict Distant Metastasis after Definitive Radio-Chemotherapy in Non-Endemic Nasopharyngeal Carcinoma
- Iron Metabolism in Nasopharyngeal Carcinoma: Multi-Omics Exploration of Tumor Progression, Immune Microenvironment, and Radiotherapy Efficacy
- Zero-Cost Customized Oral Stents Reduce Setup Errors in Nasopharyngeal Cancer Radiotherapy: Secondary Analysis of a Randomized Trial
- Gross Tumor Volume Auto Delineation Based on a Novel Multimodal Adaptive Segmentation Model in Multicenter Nasopharyngeal Carcinoma Radiotherapy
- Mechanistic of RBM3 Regulating Rad51 Alternative Splicing Mediated DNA Damage Repair Promoting Radioresistance of Nasopharyngeal Carcinoma
- Prediction Study of Prognostic Nutrition Index on the Nausea and Vomiting of Patients with Cancer Undergoing Chemotherapy or Concurrent Chemoradiotherapy Based on Cisplatin
- Development and Validation of CT-Based Dose-Volume-Radiomics Nomogram for Radiation Induced Hypothyroidism in Nasopharyngeal Carcinoma
- PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)
- RBM3 Induced Immune Resistance through Modulating Tumor Microenvironment in Nasopharyngeal Carcinoma
- The Effects of Multidimensional Individualized Clinical Management (MDICM) in Radiotherapy for Patients with Head and Neck Cancer: A Pilot Study
- Detailed analysis of recovery process of cranial nerve palsy after IMRT-based comprehensive treatment in nasopharyngeal carcinoma
- Induction Chemotherapy Followed by Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy in T4N0-1M0 Patients With Nasopharyngeal Carcinoma: A Multicenter Retrospective Study
- Mechanistic Study of Irradiated Dying NPC Cells Promoting the Metastatic Ability of Surviving NPC Cells After Radiotherapy
- Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 22 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.8%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Xi'an for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led22
- Dual-Mode Radiosensitization of Esophageal Squamous Cell Carcinoma via SOCS6-Loaded Virus-Inspired Manganese-Bismuth Bimetallic Oxide Nanoparticles.
- Integration of machine learning in biomarker discovery for esophageal squamous cell carcinoma: Applications and future directions.
- STC1 promotes esophageal squamous cell carcinoma progression and is associated with poor prognosis.
- Impact of treatment time and waiting time on outcome for esophageal squamous cell carcinoma receiving definitive chemoradiotherapy.
- Comparison of radiation esophagitis associated with daytime versus evening radiotherapy in patients with esophageal carcinoma.
- RSK4 promotes the macrophage recruitment and M2 polarization in esophageal squamous cell carcinoma.
- Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma.
- Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
- A CT-based subregional radiomics nomogram for predicting local recurrence-free survival in esophageal squamous cell cancer patients treated by definitive chemoradiotherapy: a multicenter study.
- Emerging role of cancer-associated fibroblasts in esophageal squamous cell carcinoma.
- Long-term results of induction chemotherapy for non-operable esophageal squamous cell carcinoma followed by concurrent chemoradiotherapy: a single-centre experience.
- The diagnostic performance of V' and U' variables as an objective index of pink-color sign for diagnosing esophageal cancerous lesions.
- Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma.
- Re-irradiation for local primary-recurrence esophageal squamous cell carcinoma treated with IMRT/VMAT.
- Pre-procedure oral administration of pronase improves efficacy of lugol chromoendoscopy in esophageal squamous cell carcinoma screening: a prospective, double-blinded, randomized, controlled trial.
- Clinical benefit of tunnel endoscopic submucosal dissection for esophageal squamous cancer: a multicenter, randomized controlled trial.
- Comparing N-acetylcysteine with sodium thiosulfate for relieving symptoms caused by Lugol's iodine chromoendoscopy: a randomized, double-blind trial.
- Cancer stem cells in esophageal squamous cell carcinoma.
- Overexpression of OTX1 promotes tumorigenesis in patients with esophageal squamous cell carcinoma.
- CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: A multicenter study.
- Inhibition of SOCS6 confers radioresistance in esophageal squamous cell carcinoma.
- Polygalacin D suppresses esophageal squamous cell carcinoma growth and metastasis through regulating miR-142-5p/Nrf2 axis.
All its trials on ClinicalTrials.gov, any status7
- High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy
- DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer
- The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy
- Efficacy and Safety of Endoscopic Submucosal Tunnel Dissection for Superficial Esophageal Squamous Cell Carcinoma
- Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
- Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)14
- A Longitudinal CT-Based Subregional Radiomics Nomogram for Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy: A Multicenter Study
- KDM6B Promotes the Development, Progression and Metastasis of Oesophageal Cancer through Demethylation of Histones in the LDHA Promoter Region
- Comparison of Anlotinib and S-1 Combined with Radiotherapy in the Treatment of Elderly Patients with Inoperable Esophageal Squamous Cell Cancer: An Open-Label, Phase 2, Randomized Controlled Trial
- Comparison of Radiation Esophagitis Associated with Morning vs. Evening Radiotherapy in Patients with Esophageal Squamous Cell Carcinoma
- Dolgoročni rezultati zdravljenja z indukcijsko kemoterapijo pri neoperabilnem ploščatoceličnem karcinomu požiralnika, ki ji je sledila sočasna kemoradioterapija
- Longitudinal CT Feature-Based Model for Predicting Local Recurrence Free Survival in Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: A Multicenter Study
- Value of Peritumoral Radiomics in Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Receiving Definitive (Chemo)Radiotherapy
- Clinical-Radiomics Nomogram for Risk Prediction of Esophageal Fistula in Patients with Esophageal Squamous Cell Carcinoma Treated by IMRT or VMAT
- Effect of system analysis of reactive oxygen species on prognosis and treatment decisions for patients with esophageal squamous carcinoma.
- Long-Term Results of Induction Chemotherapy for Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy
- Re-Irradiation for Locally Primary Recurrence in Esophageal Squamous Cell Carcinoma Treated with IMRT/VMAT
- Cortactin Expression Identifies Invasion Depth in Superficial Esophageal Squamous Cell Carcinoma
- Correction: Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals
- Long-Term Clinical Outcome and Safety Analysis of Superficial Esophageal Cancer Patients Receiving Definite or Adjuvant/Salvage Radiotherapy
Cancer
Hepatocellular carcinoma
肝细胞癌Led 58 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Xi'an for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led58
- A deep learning-based psi CT network effectively predicts early recurrence after hepatectomy in HCC patients.
- Surveillance and management of hepatocellular carcinoma after treatment of hepatitis C with direct-acting antiviral drugs.
- SLC25A35 enhances fatty acid oxidation and mitochondrial biogenesis to promote the carcinogenesis and progression of hepatocellular carcinoma by upregulating PGC-1α.
- The Hippo-YAP signaling pathway promotes hepatocellular carcinoma progression by inducing FHL3 expression.
- Cellular Membrane Protein GRINA is Highly Expressed and Associated with Survival Outcomes in Liver Cancer Patients.
- The oncogenic role of BCL2L12 associated with immune status in the prognosis of human hepatocellular carcinoma.
- Targeting METTL8 with Rabdosiin overcomes lenvatinib resistance in hepatocellular carcinoma.
- Intratumoral bacterial load and tertiary lymphoid structure density in hepatocellular carcinoma: association and prognostic significance.
- ASPM mediates nuclear entrapment of FOXM1 via liquid-liquid phase separation to promote progression of hepatocarcinoma.
- DDX17-Mediated Upregulation of CXCL8 Promotes Hepatocellular Carcinoma Progression via Co-activating β-catenin/NF-κB Complex.
- CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma.
- Prognostic model development using novel genetic signature associated with adenosine metabolism and immune status for patients with hepatocellular carcinoma.
- Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma.
- The Knockdown of USP34 Inhibits the Progression of Hepatocellular Carcinoma by Accelerating c-Myc Degradation.
- Performance of Ultrasonography-Based Fractal Parameters in Distinguishing Hepatocellular Carcinoma From Intrahepatic Cholangiocarcinoma.
- Constructing a disulfidptosis-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing and weighted co-expression network analysis.
- Identification of RCAN1's role in hepatocellular carcinoma using single-cell analysis.
- Development of a Novel CD8+ T Cell-Associated Signature for Prognostic Assessment in Hepatocellular Carcinoma.
- Targeting autophagy in HCC treatment: exploiting the CD147 internalization pathway.
- Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Ultrasound-guided Microwave Ablation.
- Clinical Characteristics and Prognosis of Early-Onset Hepatocellular Carcinoma: A Retrospective Cohort Study Based on Population Data.
- Long-term survival analysis of ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma conforming to the Milan criteria: primary versus recurrent HCC.
- The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
- Early versus Late Recurrence of Hepatocellular Carcinoma after Microwave Ablation: Patterns, Treatments, and Post-Recurrence Survival.
- CCDC58 is a potential biomarker for diagnosis, prognosis, immunity, and genomic heterogeneity in pan-cancer.
- The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP.
- Peritumor tertiary lymphoid structures are associated with infiltrating neutrophils and inferior prognosis in hepatocellular carcinoma.
- Downregulated mitochondrial transcription factor A enhances mycoplasma infection to promote the metastasis of hepatocellular carcinoma.
- Different 18F-FDG imaging: A rare case of liver multiple carcinomas.
- ASRGL1 downregulation suppresses hepatocellular carcinoma tumorigenesis in a CDK1-dependent manner.
- EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
- N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment.
- HMGB1-mediated elevation of KLF7 facilitates hepatocellular carcinoma progression and metastasis through upregulating TLR4 and PTK2.
- Targeting β-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma.
- Mitochondrial fission factor promotes cisplatin resistancein hepatocellular carcinoma.
- Galectin-9 expression predicts poor prognosis in hepatitis B virus-associated hepatocellular carcinoma.
- Tubulin-binding peptide RR-171 derived from human umbilical cord serum displays antitumor activity against hepatocellular carcinoma via inducing apoptosis and activating the NF-kappa B pathway.
- Low Expression of Phosphodiesterase 2 (PDE2A) Promotes the Progression by Regulating Mitochondrial Morphology and ATP Content and Predicts Poor Prognosis in Hepatocellular Carcinoma.
- Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
- A Novel Oxidative Phosphorylation-Associated Gene Signature for Prognosis Prediction in Patients with Hepatocellular Carcinoma.
- Prognostic Significance of CCDC137 Expression and Its Association with Immune Infiltration in Hepatocellular Carcinoma.
- Tertiary lymphoid structures: Associated multiple immune cells and analysis their formation in hepatocellular carcinoma.
- Overexpression of SLC25A51 promotes hepatocellular carcinoma progression by driving aerobic glycolysis through activation of SIRT5.
- Protective effect of tertiary lymphoid structures against hepatocellular carcinoma: New findings from a genetic perspective.
- Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma.
- M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
- A novel immune checkpoint-related gene signature for hepatocellular carcinoma to predict clinical outcomes and therapeutic response.
- m6A-Related Angiogenic Genes to Construct Prognostic Signature, Reveal Immune and Oxidative Stress Landscape, and Screen Drugs in Hepatocellular Carcinoma.
- Potentiality of α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) in prognosis prediction and immunotherapy response for patients with hepatocellular carcinoma.
- Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments.
- Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation.
- Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
- Increased expression of Cyclin F in liver cancer predicts poor prognosis: A study based on TCGA database.
- Total flavonoids of Radix Tetrastigma suppress inflammation-related hepatocellular carcinoma cell metastasis.
- Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway.
- Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers.
- Circulating tumour DNA methylation in hepatocellular carcinoma diagnosis using digital droplet PCR.
- Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status11
- A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma
- Exploration of Noninvasive Differential Diagnosis of Benign and Malignant Liver Tumors
- Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
- Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)
- TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma
- Sorafenib Chemoembolization Evaluation Controlled Trial
- Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function
- Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
- Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
- Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
Cancer
Stomach cancer
胃癌Led 62 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.6%.
5 hospitals in Xi'an for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 9
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingFull-time RDI for ESD: Impact on Major Adverse Events and Procedure Time
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07401303
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingEvaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07600125
Age 18 years to Not stated (registered criteria)
Led by Xijing Hospital; 3 listed hospitals as study sitesDalian, Qingdao, Wuxi, Xi'an
- RecruitingA Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07788196
Age 18 years to Not stated (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingInvestigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT06979895
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 1 listed hospital as study siteXi'an
- RecruitingThe Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
- Phase
- Not given
- Started
- 2023-08
- Registry
- NCT05956847
Age 18 years to 80 years (registered criteria)
Led by Xijing HospitalXi'an
- Not yet recruitingZanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07685704
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- Not yet recruitingTherapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT07014254
Age 18 years to 80 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingClinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2024-09
- Registry
- NCT06128252
Age 18 years to 75 years (registered criteria)
Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led62
- Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer: The Largest Systematic Reviews of 68,755 Patients and Meta-analysis.
- Comparison of short- and long-term outcomes among total laparoscopic, laparoscopic-assisted, and open total gastrectomies for advanced gastric cancer patients after neoadjuvant chemotherapy: a multicenter retrospective cohort study.
- Impact of anastomotic orientation (Upward vs. Downward) in Roux-en-Y reconstruction on duodenal stump leakage incidence after radical total gastrectomy: a retrospective comparative study.
- Short- and long-term outcomes of robotic- versus laparoscopic-assisted early-onset gastric cancer: a propensity score-matched retrospective cohort study.
- A prospective randomized study of the efficacy of continuous active warming in patients undergoing laparoscopic gastrectomy.
- Extracellular vesicle-derived lncRNA-GC1 serves as a novel biomarker for predicting and monitoring the immunotherapeutic outcomes of patients with gastric cancer.
- Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies.
- FXYD5 regulates gastric cancer cell metastasis and drug resistance by EMT modulation.
- Evaluating the prognostic significance of tumor deposits in gastric cancer and strategies for their integration into the TNM staging system: a single-center retrospective study.
- A Novel Prognostic Risk Model Based on Oxidative Stress to Predict Survival and Improve Treatment Strategies in Stomach Adenocarcinoma.
- The proteomic and transcriptomic profiles of gastric mucosa from health volunteers.
- Diagnostic efficacy of an extracellular vesicle-derived lncRNA-based liquid biopsy signature for the early detection of early-onset gastric cancer.
- Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer.
- Prediction of a Panel of Programmed Cell Death Protein-1 (PD-1) Inhibitor-Sensitive Biomarkers Using Multiphase Computed Tomography Imaging Textural Features: Retrospective Cohort Analysis.
- UPP1/ARNT positive feedback loop drives gastric cancer progression through metabolism reprogramming.
- Interaction of PHGDH with IGF2BP1 facilitates m6A-dependent stabilization of TCF7L2 mRNA to confer multidrug resistance in gastric cancer.
- The Fritillaria alkaloid peiminine acts as a chemosensitizer to potentiate oxaliplatin efficacy against gastric cancer.
- Discovery of KMT5A repressed miR-99b cluster with potential to restore chemotherapy sensitivity in gastric cancer by regulating mitochondrial complex II and affecting OXPHOS.
- The progression rate and risk factor analysis of small gastric subepithelial tumors: a systematic review and meta-analysis.
- Platinum drugs upregulate CXCR4 and PD-L1 expression via ROS-dependent pathways, with implications for novel combined treatment in gastric cancer.
- Comparison of the efficacy of TissuePatch™ versus no TissuePatch™ to seal pancreatic tissue surface for the prevention of pancreatic fistula after radical gastrectomy: study protocol for a prospective, single-center, randomized controlled t
- N6-methyladenosine reader hnRNPA2B1 recognizes and stabilizes NEAT1 to confer chemoresistance in gastric cancer.
- YTHDC1 promotes the malignant progression of gastric cancer by promoting ROD1 translocation to the nucleus.
- Biological functions of Circular RNA_LARP4/ Upstream frameshift 1 in development of gastric cancer.
- Emerging trends in early-onset gastric cancer.
- Analysis of Risk Factors for Gastric Cancer and Precancerous Lesions: A Case-Control Study.
- The inflammation score predicts the prognosis of gastric cancer patients undergoing Da Vinci robot surgery.
- miR-107 reverses the multidrug resistance of gastric cancer by targeting the CGA/EGFR/GATA2 positive feedback circuit.
- Log odds of positive lymph nodes as a novel prognostic predictor for gastric cancer: a systematic review and meta-analysis.
- Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer.
- Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer.
- Cancer associated fibroblast derived SLIT2 drives gastric cancer cell metastasis by activating NEK9.
- MG7-Ag, hTERT, and TFF2 identified high-risk intestinal metaplasia and constituted a prediction model for gastric cancer.
- Identification and validation of a novel prognostic circadian rhythm-related gene signature for stomach adenocarcinoma.
- E3 ubiquitin ligase RNF180 prevents excessive PCDH10 methylation to suppress the proliferation and metastasis of gastric cancer cells by promoting ubiquitination of DNMT1.
- DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS/MEK/ERK activity in gastric cancer cells.
- Development and validation of a ligand-receptor pairs signature to predict outcome and provide a therapeutic strategy in gastric cancer.
- Sintilimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel regimen as neoadjuvant therapy for resectable gastric cancer and biomarker exploration.
- A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.
- Relationship between gastric xanthoma, gastric precancerous lesions, and gastric cancer: A retrospective study.
- Endoscopic grading of gastric atrophy and histological gastritis staging on risk assessment for early gastric cancer: A case-control study.
- Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.
- Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer.
- Comparing intracorporeal mechanical anastomosis vs. hand-sewn esophagojejunostomy after total laparoscopic gastrectomy for esophagogastric junction cancer: a single-center study.
- Rho GTPase-activating protein 35 suppresses gastric cancer metastasis by regulating cytoskeleton reorganization and epithelial-to-mesenchymal transition.
- Sec62 promotes gastric cancer metastasis through mediating UPR-induced autophagy activation.
- Bile reflux and bile acids in the progression of gastric intestinal metaplasia.
- Circulating exosomal gastric cancer-associated long noncoding RNA1 as a noninvasive biomarker for predicting chemotherapy response and prognosis of advanced gastric cancer: A multi-cohort, multi-phase study.
- Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer.
- MiR-585-5p impedes gastric cancer proliferation and metastasis by orchestrating the interactions among CREB1, MAPK1 and MITF.
- E2F1-mediated up-regulation of TOP2A promotes viability, migration, and invasion, and inhibits apoptosis of gastric cancer cells.
- Effects of mRNA expression of five Notch ligands on prognosis of gastric carcinoma.
- A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer.
- Total Laparoscopic Uncut Roux-en-Y for Radical Distal Gastrectomy: An Interim Analysis of a Randomized, Controlled, Clinical Trial.
- Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas.
- Is intestinal metaplasia the point of no return in the progression of gastric carcinogenesis?
- Circular RNA PTK2 Accelerates Cell Proliferation and Inhibits Cell Apoptosis in Gastric Carcinoma via miR-139-3p.
- HDAC6/HNF4α loop mediated by miR-1 promotes bile acids-induced gastric intestinal metaplasia.
- Bile reflux is an independent risk factor for precancerous gastric lesions and gastric cancer: An observational cross-sectional study.
- Impact of Laparoscopic Converted to Open Gastrectomy on Short- and Long-Term Outcomes of Patients with Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
- Resveratrol inhibits bile acid-induced gastric intestinal metaplasia via the PI3K/AKT/p-FoxO4 signalling pathway.
- NEK9, a novel effector of IL-6/STAT3, regulates metastasis of gastric cancer by targeting ARHGEF2 phosphorylation.
Chinese-language papers (not in the count)8
- [Gastrointestinal hamartomatous inverted hyperplastic polyps: a clinicopathological analysis of ten cases].
- [Visualizing the evidence of robotic gastrointestinal surgery based on guideline recommendations: an evidence mapping study of gastric and colorectal cancer].
- [Comparison of short-term safety and efficacy among total laparoscopic, laparoscopy-assisted, and open radical total gastrectomy after neoadjuvant therapy: a multicenter retrospective study].
- [The correlation between No. 6 and No. 14v lymph node metastasis and the value of dissecting these lymph nodes in radical gastrectomy].
- [N6-methyladenosine (m6A) binding protein hnRNPA2B1 is highly expressed in a variety of tumors and regulates tumor immune microenvironment].
- [Patient experience in the implementation of enhanced recovery after surgery strategy after radical gastric cancer surgery].
- [Management of anastomotic leakage after laparoscopic surgery for adenocarcinoma of esophagogastric junction].
- [Functional evaluation after function-preserving gastrectomy].
All its trials on ClinicalTrials.gov, any status37
- Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
- Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time
- A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
- Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
- The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
- Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
- ERAS in Totally Laparoscopic Total Gastrectomy for Gastric Cancer
- Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer
- An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC
- Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
- A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions
- Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
- Early Diagnosis of Gastric Cancer Cachexia
- A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
- Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies
- Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer
- Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
- Study on the Effect of Bile Reflux on Gastric Cancer and Its Precancerous Lesions: a Cross-sectional Study.
- Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
- The Efficacy of Esomeprazole Premedication on Intraoperative Bleeding During Gastric ESD
- The Feasible Research of Infrared Endoscope to Diagnose Early Gastric Cancer
- Comparison of O-type Hybrid Knife and IT Knife in ESD
- Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
- Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer
- The Influence of Splenic Artery Characteristics in Gastric Cancer Surgery
- Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
- Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer
- Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy
- Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy
- A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
Cancer
Hepatoblastoma
肝母细胞瘤Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Xi'an for hepatoblastoma86 hospitals in China for hepatoblastoma
No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Chinese-language papers (not in the count)1
Cancer
Chordoma
脊索瘤Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Xi'an for chordoma84 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Cancer
Osteosarcoma
骨肉瘤Led 18 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Xi'an for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led18
- Curculigoside exhibits multiple therapeutic efficacy to induce apoptosis and ferroptosis in osteosarcoma via modulation of ROS and tumor microenvironment.
- Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome.
- The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient-Derived Xenografts and Next-Generation Sequencing.
- A deep learning model for accurately predicting cancer-specific survival in patients with primary bone sarcoma of the extremity: a population-based study.
- Characterization of myeloid signature genes for predicting prognosis and immune landscape in Ewing sarcoma.
- Deciphering the heterogeneity and immunosuppressive function of regulatory T cells in osteosarcoma using single-cell RNA transcriptome.
- Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma.
- Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study.
- A classification system of joint-salvage tumor resection in osteosarcoma of the knee: A retrospective cohort study.
- Does joint-sparing tumor resection jeopardize oncologic and functional outcomes in non-metastatic high-grade osteosarcoma around the knee?
- Is the Capanna Technique a Reliable Method for Revision Surgery after Failure of Previous Limb-Salvage Surgery?
- Intercalary tibial reconstruction with frozen tumor-bearing autograft in combination with ipsilateral fibula in limb-salvage surgery.
- Lateral Malleolus Reconstruction After Tumor Resection in Children: A Case Report and Literature Review.
- Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review.
- Use of Vascularized Fibular Epiphyseal Transfer with Massive Bone Allograft for Proximal Humeral Reconstruction in Children with Bone Sarcoma.
- Prognostic value of tumoral and peritumoral magnetic resonance parameters in osteosarcoma patients for monitoring chemotherapy response.
- The Synergistic Reducing Drug Resistance Effect of Cisplatin and Ursolic Acid on Osteosarcoma through a Multistep Mechanism Involving Ferritinophagy.
- Cryoablation-aided joint retention surgery for epiphysis involvement in osteosarcoma compared with endoprosthetic replacement.
Earlier papers (2016–2020)8
- Primary Osteosarcoma of the Liver: Case Report and Literature Review.
- Factors Influencing Osseous Union Following Surgical Treatment of Bone Tumors with Use of the Capanna Technique.
- HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.
- Honokiol induces autophagy and apoptosis of osteosarcoma through PI3K/Akt/mTOR signaling pathway.
- What are the Oncologic and Functional Outcomes After Joint Salvage Resections for Juxtaarticular Osteosarcoma About the Knee?
- [Detection and clinical significance of circulating tumor cells in osteosarcoma using immunofluorescence combined with in situ hybridization].
- Extracorporeally frozen tumour-bearing bone combined with free vascularised fibula for the intercalary reconstruction of femoral defect after resection of bony sarcoma.
- Preliminary Application of Precision Genomic Medicine Detecting Gene Variation in Patients with Multifocal Osteosarcoma.
All its trials on ClinicalTrials.gov, any status1
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Xi'an for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Regulatory roles of non-coding RNAs in programmed cell death pathways and drug resistance in gastrointestinal stromal tumors.
- An interpretable machine learning framework for automated mitosis detection in gastrointestinal stromal tumors.
- The progression rate and risk factor analysis of small gastric subepithelial tumors: a systematic review and meta-analysis.
- Development and validation of a prognostic nomogram for gastrointestinal stromal tumors in the postimatinib era: A study based on the SEER database and a Chinese cohort.
Earlier papers (2016–2020)14
- Current characteristics on small intestinal stromal tumor-a case control study.
- A multivariate prediction model for high malignancy potential gastric GI stromal tumors before endoscopic resection.
- Genetic alterations in cell cycle regulation-associated genes may promote primary progression of gastrointestinal stromal tumors.
- Clinicopathological Features and Prognosis of Gastrointestinal Stromal Tumor Located in the Jejunum and Ileum.
- Clinicopathological features, surgical strategy and prognosis of duodenal gastrointestinal stromal tumors: a series of 300 patients.
- Meta-analysis comparing laparoscopic versus open resection for gastric gastrointestinal stromal tumors larger than 5 cm.
- Pancreatic Gastrointestinal Stromal Tumor: Clinicopathologic Features and Prognosis.
- Clinicopathological features and prognosis of mesenteric gastrointestinal stromal tumor: evaluation of a pooled case series.
- Clinicopathological feature and prognosis of primary hepatic gastrointestinal stromal tumor.
- Clinicopathological features and prognosis of coexistence of gastric gastrointestinal stromal tumor and gastric cancer.
- Combination of PLR, MLR, MWR, and Tumor Size Could Significantly Increase the Prognostic Value for Gastrointestinal Stromal Tumors.
- Clinicopathologic Features and Clinical Outcomes of Esophageal Gastrointestinal Stromal Tumor: Evaluation of a Pooled Case Series.
- Clinicopathological features and prognosis of colonic gastrointestinal stromal tumors: evaluation of a pooled case series.
- Clinicopathological features and prognosis of omental gastrointestinal stromal tumor: evaluation of a pooled case series.
All its trials on ClinicalTrials.gov, any status1
Cancer
Neuroblastoma
神经母细胞瘤Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Xi'an for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Cancer
Ewing sarcoma
尤文肉瘤Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Xi'an for Ewing sarcoma134 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.
- Open trials led
- 0
- recruiting or about to
4 hospitals in Xi'an for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingIsatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07663253
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status4
- A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
- Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Xi'an for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia
No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Xi'an for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgG4-related disease
IgG4相关性疾病Led 1 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Xi'an for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
Moyamoya disease
烟雾病Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Xi'an for moyamoya disease47 hospitals in China for moyamoya disease
No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 3 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Xi'an for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
Other diseases
Takayasu arteritis
大动脉炎Led 3 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Xi'an for Takayasu arteritis100 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Brain computed tomography perfusion alterations in patients with Takayasu arteritis with steno-occlusive carotid arteries: a retrospective study.
- The establishment and validation of reference intervals for plasma Pentraxin-3 in healthy volunteers and patients with Takayasu's arteritis.
- Acute myocardial infarction with left main coronary artery ostial negative remodelling as the first manifestation of Takayasu arteritis: a case report.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)3
- Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu's arteritis patients.
- Contrast-enhanced Ultrasonography for Monitoring Arterial Inflammation in Takayasu Arteritis.
- [Association between platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with disease activity in Takayasu arteritis patients].
All its trials on ClinicalTrials.gov, any status1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Xi'an for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Xi'an for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)4
- Identification of two novel insertion abnormal transcripts in two Chinese families affected with Dystrophinopathy.
- [A predictive analysis of the association between clinical phenotypes and genotypes in children with Becker muscular dystrophy/Duchenne muscular dystrophy].
- [Incidental discovery of DMD gene deletions by chromosomal microarray analysis].
- A retrospective analysis of 237 Chinese families with Duchenne muscular dystrophy history and strategies of prenatal diagnosis.
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Xi'an for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led 10 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.4%.
- Open trials led
- 0
- recruiting or about to
7 hospitals in Xi'an for IgA nephropathy300 hospitals in China for IgA nephropathy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPhase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07390123
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changchun, Changsha, Huangshan City, Linyi, Shanghai, Wuhu, Xi'an, Zhanjiang
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led10
- Exploring the crosstalk molecular mechanisms between IgA nephropathy and Sjögren's syndrome based on comprehensive bioinformatics and immunohistochemical analyses.
- Immune checkpoint activity exacerbate renal interstitial fibrosis progression by enhancing PD-L1 expression in renal tubular epithelial cells.
- Serum Long Noncoding RNA H19 and CKD Progression in IgA Nephropathy.
- Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria.
- The clinicopathological characteristics and outcomes of IgA nephropathy with predominant lambda or kappa light-chain deposition.
- Expansion of Escherichia-Shigella in Gut Is Associated with the Onset and Response to Immunosuppressive Therapy of IgA Nephropathy.
- Low-Dose Corticosteroid Combined With Mycophenolate Mofetil for IgA Nephropathy With Stage 3 or 4 CKD: A Retrospective Cohort Study.
- The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.
- Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports.
- Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)5
- A Comparative Study of the Gut Microbiota Associated With Immunoglobulin a Nephropathy and Membranous Nephropathy.
- Renal survival and risk factors in IgA nephropathy with crescents.
- Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria.
- Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.
- The landscape and diagnostic potential of T and B cell repertoire in Immunoglobulin A Nephropathy.
All its trials on ClinicalTrials.gov, any status3
Other diseases
Gaucher disease
戈谢病Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Xi'an for Gaucher disease40 hospitals in China for Gaucher disease
No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Niemann–Pick disease type C
尼曼-匹克病 C 型Led 1 of the 16 English-language PubMed papers on Niemann–Pick disease type C with an author in mainland China, 2021–2025: 6.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Xi'an for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C
No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 17 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 5.7%.
4 hospitals in Xi'an for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
Open trials with this hospital 7
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingFIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07296458
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 1 listed hospital as study siteGuangzhou, Xi'an
- RecruitingFenofibrate in Primary Biliary Cholangitis: a Real World Study
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT06755151
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingFenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT06755541
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingFenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Phase
- Phase 2/Phase 3
- Started
- 2023-02
- Registry
- NCT05749822
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan'an, Zhengzhou
- RecruitingFenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Phase
- Phase 3
- Started
- 2023-02
- Registry
- NCT05751967
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an
- RecruitingFenofibrate in Patients With Primary Biliary Cholangitis (PBC)
- Phase
- Phase 2/Phase 3
- Started
- 2017-04
- Registry
- NCT06365424
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingSeladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06051617
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led17
- The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine.
- The prognostic value of anti-gp210 and anti-centromere antibodies in patients with primary biliary cholangitis: Enhancing the prognostic utility on the GLOBE scoring system.
- Risk stratification for patients with primary biliary cholangitis: early versus advanced-stage or non-cirrhosis versus cirrhosis?
- Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment.
- Hypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary Cholangitis.
- Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria.
- Differences in the perceptions of patients with primary biliary cholangitis and physicians from various hospital departments: An online survey.
- Innate lymphoid cell subsets in the pathogenesis of primary biliary cholangitis.
- Dissecting causal relationships between primary biliary cholangitis and extrahepatic autoimmune diseases based on Mendelian randomization.
- Integrative bioinformatics analysis and experimental validation of key biomarkers for risk stratification in primary biliary cholangitis.
- Laboratory risk factors for coexistent primary biliary cholangitis in patients with Sjögren's syndrome: a retrospective study.
- Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
- Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.
- Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial.
- Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
- Primary biliary cholangitis: personalized medicine for optimal therapeutic opportunities.
- Decreased infiltration of CD4+ Th1 cells indicates a good response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis.
Chinese-language papers (not in the count)4
Earlier papers (2016–2020)6
- A nomogram based on pretreatment clinical parameters for the prediction of inadequate biochemical response in primary biliary cholangitis.
- [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
- [Study the role of lysosome-associated membrane protein type 2A for immune-mediated liver injury of primary biliary cholangitis].
- [Screening of familial primary biliary cholangitis and research on low-frequency mutations by whole-exome sequencing].
- [Primary biliary cholangitis and bile acid metabolism].
- [An interpretation of 2017 EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis].
All its trials on ClinicalTrials.gov, any status17
- FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
- Fenofibrate in Primary Biliary Cholangitis: a Real World Study
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
- Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)
- Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)
- Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis
- Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis
- Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid
- Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid
- A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
- Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Xi'an for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Xi'an for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other linked evidence
Getting in touch
Name card to show staff or a driver
空军军医大学西京医院
Xijing Hospital
西安
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Xijing Hospital of Digestive Diseases; Xijing Hospital of Digestive Disease; XiJing Hospital; Xijing Hospital of The Fourth Military Medical University; Xijing Hospital Fourth Military Medical University; Xijing Hospital Affiliated to Fourth Military Medical University; Air Force Medical University Xijing Hospital; Xijing Hospital of Air Force Medical University